Research

Description of efforts by the big drug companies to develop an Ebloa vaccine
THE NEW YORKER    By Vauhine Vara                        Nov. 25, 2014

"...why this race to create an Ebola vaccine among Merck, GlaxoSmithKline, and Johnson & Johnson—three of the world’s biggest drug manufacturers? For years, pharmaceutical companies didn’t invest much in vaccines, partly because they were so costly and complicated to produce: they’re often made out of live bacteria, which are notoriously difficult to work with. But, over the past several years, companies have realized that the difficulties of making vaccines could be an asset, because they can make it more difficult for generic-drug companies to create copycat versions than for prescription drugs. The vaccine market has also been growing more quickly than the prescription-drug market. The World Health Organization estimates, based on various sources, that global vaccine sales rose from five billion dollars in 2000 to twenty-four billion dollars last year...."

Read complete article
http://www.newyorker.com/business/currency/race-ebola-vaccine

TIME MAGAZINE By Alexandra Sifferlin                          Nov. 25, 2014
 By  Alexandra Sifferlin                       

Scientists are scurrying to get their Ebola vaccines through the necessary safety trials before they can be used widely. That includes the University of Maryland School of Medicine, which recently kicked off the latest step in their research: figuring out the appropriate dosing for the vaccine that’s both effective and safe.

The University of Maryland is one of a handful of institutions involved in the testing of an experimental but promising vaccine developed by the National Institutes of Health’s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK). The hope is that the vaccine will pass through early trials needed by end of December so that the World Health Organization (WHO) and a panel of outside experts can decide whether to move on to a large efficacy trial, which would mean vaccinating a lot of people in West Africa to see how well it works.

UPDATE:   Additonal information on the WHO discussions of potential Ebola treatments.

(Scroll down)

REUTERS                                                      Nov. 14, 2014

By Tom Miles

GENEVA --The World Health Organization (WHO) has begun assessing more than 120 potential treatments for Ebola patients, it said on Friday, but so far has found none that definitely work, and some that definitely do not....

The apparent effect of ZMapp or other drugs that have been tried may simply be a result of the good care that the patients had received, or the fact that they were well-nourished before they fell sick, or because of other medicines, Friede said.

Medecins Sans Frontieres plans to start trials next month of the drugs brincidofovir, from the U.S. firm Chimerix, and favipiravir, from Japan's Fujifilm, and to see how well blood plasma from Ebola survivors may work in curing those still infected....

Read complete story

http://www.reuters.com/article/2014/11/14/us-health-ebola-who-treatments-idUSKCN0IY1CR20141114

-0-

Additional Information:

NEW ENGLAND JOURNAL OF MEDICINE                                                                  Nov. 12, 2014

Eric J. Rubin, M.D., Ph.D., and Lindsey R. Baden, M.D.

The Journal has now published detailed clinical information about three patients transferred from West Africa to the United States or Germany in the midst of their illness.

See details of the treatment

http://www.nejm.org/doi/full/10.1056/NEJMe1412744